Gasper LaRosa is co-chair of Jones Day's PTAB Litigation Practice and is a leading pharmaceutical and biotechnology patent lawyer as recognized by clients and his peers. He has more than 15 years of client-focused experience litigating high-profile patent infringement cases involving pharmaceutical products, medical devices, chemical manufacturing processes, and business methods. He has tried patent cases to juries and to the bench in several federal district courts. In addition, Gasper has broad experience representing clients as lead counsel in USPTO post-grant proceedings.
Gasper's practice focuses particularly on Hatch-Waxman (ANDA), biosimilar (BPCIA), and other patent litigation on behalf of pharmaceutical and biotechnology companies. He has represented major pharmaceutical companies in the enforcement of patents covering some of the world's most successful drug products and drug delivery systems. His representations include litigations and PTAB proceedings concerning biologics (e.g., conjugate vaccines) as well as small molecule blockbuster drugs including OxyContin® (oxycodone hydrochloride extended release tablets), Butrans® (buprenorphine patch, extended release), Androgel® (transdermal testosterone replacement therapy), Thalomid® (a treatment of multiple myeloma and erythema nodosum leprosum), Revlimid®, Skelaxin® (a muscle relaxant), Avinza® (an extended release morphine sulphate pain reliever), and Univasc® and Uniretic® (ACE inhibitors).
Gasper is a member of the American Bar Association, the PTAB Bar Association, the Federal Circuit Bar Association, the New York Intellectual Property Law Association, and the American Institute of Chemical Engineers. He also serves as a member of the Pharmaceutical & Biotechnology Issues Committee of the Intellectual Property Owners Association.
Trial Court Denies Amendment of Contentions To Add Reexam Claims Following Successful IPR, PTAB Litigation Blog
Precedential: PTAB Considers § 314(a) Factors Even When Denying Under § 325(d), PTAB Litigation Blog
Delaware District Dismisses BPCIA "Private Right" Claim; Says Controversy not Sufficiently Immediate
- March 26, 2019
Hatch-Waxman and BPCIA Fundamentals: Understanding Follow-On Products and the Rules for Generic Entry, FDA Boot Camp
- November 29, 2018
Privity at the PTAB since RPX
- June 20, 2017
Preparing for Litigation Before Litigation, 36th Global Litigation Confex
- October 27, 2015
Global Legal ConfEx - IP LItigation Around the World
- September 18, 2014
The Food and Drug Law Institute - Celebrating the 30th Anniversary of the Hatch-Waxman Amendments: The Past, Present and Future of Generic Drugs
- August 1, 2013
Successfully Navigating FDA Citizen Petitions and Responses
- May 7, 2010
Foreign Exchange: The Impact and Role of Foreign Forums on U.S. Litigation, AIPLA 2010 Spring Meeting
- St. John's University (J.D. 2001); Rensselaer Polytechnic Institute (B.S. in Chemical Engineering 1995)
- New York, U.S. Supreme Court, U.S. District Court for the Southern District of New York, U.S. Court of Appeals for the Federal Circuit, and registered to practice before the U.S. Patent and Trademark Office
- Super Lawyers "Rising Star" (2013)